First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy
Status:
Terminated
Trial end date:
2021-09-23
Target enrollment:
Participant gender:
Summary
In this study, the new drug called PPSGG (PN-1007) will be tested. Preliminary studies
conducted in animals suggest PPSGG (PN-1007) might be a good treatment for reducing levels of
anti-MAG antibodies in patients with anti-MAG neuropathy.
This is the first research of PPSGG (PN-1007) in people and its main purpose is to test its
safety and acceptability in patients. In this study it will be examined how the drug is
changed by and removed from the body and checked for signs that the drug may be truly
effective against anti-MAG neuropathy. PPSGG (PN-1007) will be tested at several different
doses.